Literature DB >> 9133545

Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas.

R S Heller1, T J Kieffer, J F Habener.   

Abstract

Glucagon-like peptide I (GLP-I), an intestine-derived incretin hormone, is a potent stimulator of insulin and somatostatin secretion. In some studies, GLP-I is an inhibitor of glucagon secretion. It remains uncertain, however, whether the effect of GLP-I on the inhibition of glucagon secretion is direct, owing to interactions with GLP-I receptors on alpha-cells, or indirect, via paracrine suppression by insulin or somatostatin. The localization of the GLP-I receptor on insulin and somatostatin-producing cells in the islets is well established. Whether the GLP-I receptor also resides on the glucagon-producing alpha-cells remains controversial and is reported to be absent on rat alpha-cells. To investigate the distribution of the GLP-I receptor on islet cells, we examined the expression of GLP-I receptor mRNA in phenotypically distinct islet cell lines and islets, and the presence of immunoreactive GLP-I receptor in dispersed rat islet cells using a specific antiserum. GLP-I receptor mRNA was readily detected by reverse transcription-polymerase chain reaction (RT-PCR) in both rat islets and in established islet cell lines representing distinct alpha-, beta-, and delta-cell phenotypes. In addition, GLP-I receptor expression was detected in single rat alpha-cells by single-cell RT-PCR. In dispersed rat islet cells analyzed by double immunofluorescent staining, 90% of the insulin, 76% of the somatostatin, and 20% of the glucagon positive cells colocalized with the GLP-I receptor immunoreactivity. Thus, a substantial population of glucagon immunoreactive a-cells express the GLP-I receptor. These findings imply that GLP-I may have a direct receptor-mediated action in the regulation of the physiological functions on a substantial subpopulation of alpha-cells. We suggest that a possible role for GLP-I receptors on alpha-cells may be to provide positive autocrine feedback control on glucagon secretion during fasting and/or to dampen the potent paracrine suppression of glucagon secretion by insulin during feeding.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9133545     DOI: 10.2337/diab.46.5.785

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  46 in total

1.  Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

Authors:  Jens Juul Holst
Journal:  Diabetologia       Date:  2013-07-03       Impact factor: 10.122

Review 2.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

3.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Authors:  J Schirra; K Sturm; P Leicht; R Arnold; B Göke; M Katschinski
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

Review 4.  Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.

Authors:  Gerhard H Scholz; Holger Fleischmann
Journal:  Ther Adv Endocrinol Metab       Date:  2014-10       Impact factor: 3.565

Review 5.  α-cell role in β-cell generation and regeneration.

Authors:  Joel F Habener; Violeta Stanojevic
Journal:  Islets       Date:  2012 May-Jun       Impact factor: 2.694

Review 6.  Physiology of incretins in health and disease.

Authors:  Carolyn F Deacon; Bo Ahrén
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.

Authors:  Taichi Nakamura; Tetsuhide Ito; Masahiko Uchida; Masayuki Hijioka; Hisato Igarashi; Takamasa Oono; Masaki Kato; Kazuhiko Nakamura; Koichi Suzuki; Robert T Jensen; Ryoichi Takayanagi
Journal:  Lab Invest       Date:  2013-11-11       Impact factor: 5.662

Review 9.  Incretin-based therapies in type 2 diabetes mellitus.

Authors:  Chee W Chia; Josephine M Egan
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

10.  Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation.

Authors:  Zhengyu Liu; Joel F Habener
Journal:  J Biol Chem       Date:  2008-01-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.